Exiqon A/S
Exiqon A/S announces financial calendar for 2015

DGAP-News: Exiqon A/S

27.10.2014 / 16:06

---------------------------------------------------------------------

Copenhagen, 2014-10-27 16:06 CET (GLOBE NEWSWIRE) -- Exiqon A/S (NASDAQ
Copenhagen: 'EXQ') today announced the expected dates for Exiqon A/S' annual
general meeting and financial reporting in 2015. 

Announcement of full-year results 2014:                         30 January 2015 
--------------------------------------------------------------------------------
Deadline for shareholders' proposal to the annual general       05 February 2015
 meeting:                                                                       
--------------------------------------------------------------------------------
The annual general meeting is scheduled to be held on:          19 March 2015   
--------------------------------------------------------------------------------
Interim report for the period 1 January 2015 to 31 March 2015:  07 May 2015     
--------------------------------------------------------------------------------
Interim report for the period 1 January 2015 to 30 June 2015:   25 August 2015  
--------------------------------------------------------------------------------
Interim report for the period 1 January 2015 to 30 September    26 October 2015 
 2015:                                                                          
--------------------------------------------------------------------------------

Additional information
Lars Kongsbak, President and CEO, tel. +45 4566 0888 (cell: +45 4090 2101)
Hans Henrik Chrois Christensen, CFO, tel. +45 4566 0888 (cell: +45 4090 2131)

About Exiqon
Exiqon operates in two business areas. Exiqon Life Sciences is a leading
provider of flexible solutions for RNA analysis. Exiqon Life Sciences' research
products are used by academia, biotech and pharmaceutical companies around the
world to make groundbreaking discoveries about the correlation between gene
activity and the development of diseases. Exiqon Diagnostics collaborates with
pharmaceutical and diagnostic companies to develop novel molecular diagnostic
tests for early detection of diseases which can help physicians make treatment
decisions based on the tools developed by Exiqon Life Sciences. Exiqon is
listed on NASDAQ Copenhagen. For more information about us, please visit
www.exiqon.com
News Source: NASDAQ OMX



---------------------------------------------------------------------

27.10.2014 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language:    English       
Company:     Exiqon A/S    
 
 
             Denmark       
ISIN:        DK0060077758  
 
 
End of News    DGAP News-Service  
---------------------------------------------------------------------  
293535 27.10.2014